Storyline
New insights into tumor immune evasion and therapeutic targets in epithelial cancers
Coverage centers on: bioRxiv (all subjects).
Published 2026-07-09 17:38 UTCUpdated 2026-07-10 11:48 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (1 domains)domains are deduped. counts indicate coverage, not truth.1 top source shown
limited source diversity in top sources
Overview
Coverage centers on: bioRxiv (all subjects).
Score total
0.73
Momentum 24h
2
Posts
2
Origins
1
Source types
1
Duplicate ratio
0%
Why now
- Recent multi-omics and single-cell analyses provide detailed tumor microenvironment insights.
- Emerging resistance to PD-1 blockade highlights need for novel targets.
- Preclinical evidence supports combining TAOK3 inhibition with chemotherapy for cervical cancer.
Why it matters
- Understanding tumor immune evasion mechanisms can improve immunotherapy strategies.
- Identifying molecular drivers like NECTIN4 and TAOK3 offers new therapeutic targets.
- Enhancing chemotherapy and immunotherapy efficacy could improve patient outcomes in epithelial cancers.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: seed.
- Current status: open.
- 2 current source-linked posts are attached to this storyline.
All evidence
All evidence
TAOK3 inhibition constrains invasion, potentiates paclitaxel, and reprograms the tumor microenvironment toward anti-tumor immunity in cervical cancer
bioRxiv (all subjects) · biorxiv.org · 2026-07-10 11:48 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 1Origin domains: 1Duplicates: -
Showing 1 / 0
Top publishers (this list)
- bioRxiv (all subjects) (1)
Top origin domains (this list)
- biorxiv.org (1)